FDA approves gene therapy for deafness

Gene therapy for deafness just crossed from experiment to approved medicine. The FDA approved Otarmeni on April 23, 2026, for a specific inherited form of severe hearing loss caused by mutations in the OTOF gene. That matters because this is not a hearing aid, and not a cochlear implant — it is an attempt to fix the broken molecular step inside the ear itself. For families with this mutation, the gap has always been brutal: the biology was known, but there was no way to repair it. (fda.gov) ### What exactly got approved? Otarmeni — generic name lunsotogene parvec-cwha — is a one-time gene therapy from Regeneron for pediatric and adult patients with severe-to-profound or profound sensorineural hearing loss tied to confirmed biallelic OTOF variants, as long as outer hair cell function is preserved and (fda.gov)apy for genetic hearing loss. (fda.gov) ### What does OTOF have to do with hearing? The OTOF gene makes otoferlin, a protein inner hair cells need to pass sound information onward to the auditory nerve. If both copies are not working, sound reaches the ear but the signal handoff fails — basically like a microphone that captures sound but never sends the(fda.gov)f congenital hearing loss. (fda.gov) ### How does the therapy work? The catch is that OTOF is too large to fit neatly into a single standard AAV package. Otarmeni gets around that by using two AAV1 vectors, delivered surgically into the cochlea with a syringe, catheter, and infusion pump. Together they carry a functional copy of the gene into inner hair cells so those cells can make otoferlin again and restart auditory signaling. That dual-vector design is a big technical milestone on its own. (fda.gov) ### Why are people paying attention to the trial? Because the hearing gains were not subtle. Regeneron says accelerated approval was based on CHORD trial data showing 80% of participants met or beat the primary hearing endpoint, and with longer follow-up 42% reached normal hearing levels that included whispers. The approval is accelerated, which means confirmatory follow-up still matters, but those numbers are why this moved so fast. (investor.regeneron.com) ### Why did the FDA move so quickly? Otarmeni went through the FDA Commissioner’s National Priority Voucher pilot, which is meant to speed review of therapies for serious unmet needs. The agency says approval came 61 days after the biologics license application filing — tied for the fastest BLA approval in modern FDA history — and it was the sixth approval under that pilot. That speed is unusual, especially for a complex gene therapy plus delivery-device combination. (fda.gov) ### Does this replace cochlear implants? No — not broadly. Otarmeni is approved for one genetic subtype, with anatomical and functional limits. But it changes the treatment logic. Instead of bypassing the damaged biology with an implant, this approach tries to restore the missing protein inside the ear. That is why trial investigators are talking about “natural hearing” rather than just sound detection. (fda.gov) ### Is this a one-off, or the start of something? Probably the start of something. The company already has a long-term follow-up study running through 2033 to watch durability and delayed safety, which is standard for gene therapies but especially important here because the target is a sensory function people use constantly. More broadly, once one inner-ear gene therapy clears FDA review, the path for others gets much more real. (clinicaltrials.gov) ### Bottom line? This approval is narrow, but the breakthrough is wide. Otarmeni does not solve deafness in general. It does show that a gene therapy can move from remarkable hearing-restoration data to an FDA-approved product for a defined inherited cause of deafness — and that is a very different place than the field was even a year ago. (fda.gov)national-priority-voucher))